anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PRESTALIA can cause symptomatic hypotension. Symptomatic hypotension is most likely to occur in patients who have been volume- or salt-depleted as a result of prolonged diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting.

In patients at risk of excessive hypotension, start PRESTALIA therapy under close medical supervision. Follow patients closely for the first 2 weeks of treatment and whenever the dose of PRESTALIA is increased or a diuretic is added or its dose increased.

If excessive hypotension occurs, immediately place patient in a supine position and, if necessary, treat patient with an intravenous infusion of physiological saline. PRESTALIA treatment can usually be continued following restoration of volume and blood pressure.

Patients with severe aortic stenosis may be more likely to experience symptomatic hypotension. Because of the gradual onset of action, acute hypotension is unlikely.

Surgery/Anesthesia

In patients undergoing major surgery or during anesthesia with agents that produce hypotension, PRESTALIA may block angiotensin II formation secondary to compensatory renin release. If hypotension occurs and is considered to be due to this mechanism, it can be corrected by volume expansion.
All participants that will be assigned to supervised isometric handgrip training will train three times per week, during 24 weeks. They will perform a bout of isometric handgrip exercise: four sets of 2-min of isometric contractions (using alternate hands) at 30% of maximal voluntary contraction.
PROBLEM TO BE SOLVED: To obtain a jelly agent for medical use filled in a container capable of simply and directly administering the jelly agent from the container housing the jelly agent therein into the interior of a mouth without using an administration tool, etc. SOLUTION: This jelly agent 1 for medical use is sealed in a rodlike baglike container 2 formed of a thermally fusible film and having the interior sealed by thermal fusion. The container 2 is provided with a trunk part 3 and heat sealed parts 40 respectively at one end each in the longitudinal direction and a lateral part and the trunk part 3 has a part divided in the longitudinal direction in which a gas is sealed and a part in which the jelly agent 1 for the medical use is sealed. The inner gas pressure is higher than the outer gas pressure and the trunk part 3 is kept in a distended state. A notch 50 is provided in the heat sealed part 40 in the lateral part of the container 2 at a position on the inside of 2-5 mm from one end on the side of the part in which the jelly agent 1 for the medical use is sealed in the longitudinal direction of the trunk part 3.  The jelly agent 1 for the medical use filled in the container 2 forming an opening by unsealing the container 2 from the notch 50 and the part in which the gas is sealed is then compressed with fingers to push out the jelly agent 1 for the medical use from the container 2 while retaining the shape of the jelly agent 1.
Test patients receive bone augmentation and selective decorticalisation (corticotomy) and 1 week postop. OTM.
Subjects without a known psychiatric disorder and/or unstable medical illness are assigned to the control group. The control subjects are not given CoQ10.
The invention relates to a new anti-tumoral therapy agent based on liposome-encapsulated cytostatic agents and/or the metabolites thereof. The invention can be used in the pharmaceutical industry and in medicine. The aim of the invention is to build up drug targeting to combat cancer through suitable carrier systems. The invention is characterized by the fact that it clearly increases the concentration of cytostatic agents and residence time in tumors. At the same time, toxic side-effects on the remaining organs are reduced. The inventive agent contains PEG, immuno or immuno/PEG liposome-encapsulated cytostatic agents and/or the metabolites thereof, degradable starch particles and/or gelatin and/or nanoparticles, contrast agents containing iodine, gadolinium or magnetite. A preferred agent is characterized by the cytostatic agent Carboplatinum, encapsulated in SUV-PEG, starch particle Spherex or Gelfoam and the contrast agent Gadolinium-DTPA.
This invention relates to a novel DNA sequence encoding a bHLH transcription factor in vertebrates, preferably mammals, e.g. in mice or humans, as well as the expressed transcription factor. The invention further relates to vectors containing said DNA sequences and host cells transformed by these vectors. Furthermore, the invention encompasses antibodies specific for the transcription factors as well as the use of the DNA sequences and transcription factors in the diagnosis or therapy of neurodegenerative diseases, e.g. Parkinson's disease. The present invention further relates to an ex vivo method of producing dopaminergic cells and the therapeutic use of these dopaminergic cells.
PCT No. PCT/EP92/02228 Sec. 371 Date Apr. 26, 1994 Sec. 102(e) Date Apr. 26, 1994 PCT Filed Sep. 28, 1992 PCT Pub. No. WO93/08470 PCT Pub. Date Apr. 29, 1993The immunological activity of certain bioactive substances is determined by treating a human peripheral blood leukocyte (PBL) culture or a suspension of BALB/c mice resident peritoneal cells (RPC), with a solution of the substance to be tested in order to induce production of cytokines which then are determined according to standard identification methods; amplification of the results may be achieved by admixing, to the solution to be tested, a non-steroidal anti-inflammatory drug, preferably indomethacin. The method is also useful for determining the immunological response of a human individual to a therapy using a cytokine inducing substance.
An innovation includes new knowledge enabling the novel structure of receptor action to be created. The validations mentioned below are the underlying novel components of this structure. The creation of complexes: ligand -> receptor -> lipids according to this scheme: receptor -> ganglioside -> cerebroside -> sphingomyelin with inter-carbohydrate and inter-lipid hydrogen bonds. The modulation of the structure of the inner layer of the membrane for the creation of combination sites for mobile proteins such as protein kinase C or protein G through very long chains of the outer layer. The validation of endocytosis as a means of negative regulation (feedback) of the enzymes of the inner layer, especially protein kinase C. The validation of the micellar structure (fatty chains inside) and rotatory structure of Ca<2+> transport through the membrane with the assistance of phospholipase A2 and acyltransferase. Other fundamental points of molecular and cell biology are also created: the most general and commonest structures of receptor action with the synchronisation of propagation of the signal with the feedback actions; the structure of endocytosis with the increase of a degree of the unsaturation of fatty acids; the bases of the structure of the dynamic and static equilibrium of the receptors in the membrane; the structure of the action of coated wells; the structure of cell motility; the structure of the action of pertussis toxin; the complete structure of the interaction between B and T lymphocytes. As important practical consequences of this structure, novel preparations against the ten or so mental diseases - sphingolipidoses, against cancer and for carrying out anaesthesia are proposed. The means of arresting cell activity at its surface are proposed on the basis of the fundamental structure. They include: a) preparations with 2-pyridinethione 1-oxide against insects, protozoa and helminths; b) preparations, manifestly prospective, with antibodies having modified charges against viruses (including HIV virus) and bacteria. The transcription and translation of antibodies in the body using the genomes of harmless viruses and bacteria are also proposed. The creation of universal maps is proposed, corresponding to the action of particular receptors according to this fundamental structure with the novel curative preparations for bringing the pathological state of receptor action closer to the normal state.
The present invention discloses a nanometer composite skin disinfection emulsion and a preparation method thereof. The disinfection emulsion comprises the following components: chlorhexidine acetate, zinc oxide, ethylene diamine tetraacetic acid, emulsifier and water. The emulsifier is composed of vegetable oil, tributyl phosphate and Triton x-100. Total volume ratio among the vegetable oil, the tributyl phosphate and the Triton is 2-8:1:1. The concentration of the chlorhexidine acetate is 0.5-3g/L. The concentration of the zinc oxide is 0.01-0.5g/L. The particle size of the zinc oxide is 50-100nm. The concentration of the ethylene diamine tetraacetic acid is 0.01-0.2g/L. The disinfection emulsion has the following advantages: wide antimicrobial spectrum of the inorganic antiseptic, high lasting effect, high heat resistance, no easy drug resistance, capability of obtaining an ideal skin disinfection effect, and important application value.
The dosage of nisoldipine extended-release tablets must be adjusted to each patient’s needs. Therapy usually should be initiated with 17 mg orally once daily, then increased by 8.5 mg per week or longer intervals, to attain adequate control of blood pressure. Usual maintenance dosage is 17 mg to 34 mg once daily. Blood pressure response increases over the 8.5 mg to 34 mg daily dose range but adverse event rates also increase. Doses beyond 34 mg once daily are not recommended. Nisoldipine extended-release tablets have been used safely with diuretics, ACE inhibitors, and beta-blocking agents. Patients over age 65, or patients with impaired liver function, are expected to develop higher plasma concentrations of nisoldipine. Their blood pressure should be monitored closely during any dosage adjustment. A starting dose not exceeding 8.5 mg daily is recommended in these patient groups. Nisoldipine extended-release tablets should be administered orally once daily. Nisoldipine extended-release tablets should be taken on an empty stomach (1 hour before or 2 hours after a meal). Grapefruit products should be avoided before and after dosing. Nisoldipine extended-release tablets are an extended release dosage form and tablets should be swallowed whole, not bitten, divided or crushed.
Strength training for leg muscles during10 weeks, 3 times a week: hack squat and plantar flexion, standing upright in a hack squat machine and lying down in a calf rise machine. Exercises will be carried out at 85% of 1-RM intensity under supervision at the institution where participants are having their SUD treatment.
This study aimed to elucidate the mechanism of Wenzheng Jiedu Powder Modified Formula (WJPMF) in treating neuropathic pain (NP). Network pharmacology and experimental verification were integrated to explore the therapeutic effects and key targets of WJPMF. Active components, corresponding target genes, and absorption, distribution, metabolism, and excretion (ADME) genes of WJPMF against NP were screened from public databases. Network analysis and molecular docking were conducted to identify key targets and verify binding abilities. In vivo experiments were performed on spared nerve injury (SNI) rats to assess the analgesic effects and regulatory mechanisms of WJPMF. WJPMF significantly improved pain behaviors in SNI rats by regulating ATP-binding cassette transporter A1 (ABCA1), peroxisome proliferator-activated receptor alpha (PPARA), peroxisome proliferator-activated receptor gamma (PPARG), and superoxide dismutase 2 (SOD2) expression, which were key targets involved in the peroxisome proliferator-activated receptor (PPAR) signaling pathway. WJPMF shows promising therapeutic potential for NP through the modulation of specific targets, offering a novel therapeutic strategy for managing NP.
Centella asiatica (Indian pennywort) is a green leafy vegetable containing centelloside' (triterpenoid), a key phytochemical component in traditional medicine. Being a glycophytic species, they exhibit decline in growth performance and yield traits when subjected to water-deficit (WD) conditions. Glycine betaine (GB) is a low molecular-weight organic metabolite that plays a crucial role in abiotic stress conditions in higher plants. The objective of this study was to investigate the potential of GB in alleviating water-deficit stress (in terms of morphological and physiological responses) in two different genotypes of Indian pennywort, "Nakhon Pathom" (NP; high centelloside-yielding genotype) and "Pathum Thani" (PT; low centelloside-yielding genotype). The genotypes of Indian pennywort were propagated by stolon cutting and transplanted into plastic bags containing 2 kg of garden soil. At the flower-initiation stage (30 days after transplantation), uniform plant material was treated exogenously with 0 (control), 25, and 50 mM GB at 100 mL per plant (one-time foliar spray) and then divided into two groups, 1) well watered (WW; irrigated daily with 400 mL fresh water; 98% field capacity) and 2) water deficit (WD; withheld water for 14 days; 72% field capacity). Foliar application of GB (25 mM) significantly improved leaf osmotic potential in NP under WD conditions via osmotic adjustment by free proline and fructose. Differences in leaf temperature (Tleaf) between WD and WW in NP were maximized (+ 1.93 °C) and the gap of Tleaf was reduced in the case of 25-50 mM GB application. Similarly, crop water stress index (CWSI) in NP and PT plants under WD condition was significantly increased by 1.95- and 1.86-fold over the control, respectively; however, it was significantly decreased by exogenous GB application. Increasing Tleaf and CWSI in drought-stressed plants was closely related to stomatal closure, leading to reduced gas exchange parameters, i.e., stomatal conductance (gs), transpiration rate (E), net photosynthetic rate (Pn), and intercellular CO2 concentration (Ci), and consequently decreased plant biomass and total centelloside yield. Overall physiological, morphological, and secondary metabolite traits were enhanced in NP under WD conditions using 25 mM GB exogenous application compared with the control. The study highlights the significance of GB in Indian pennywort production under limited water irrigation (water deficit) with higher vegetable yield and phytochemical stabilization.
BACKGROUND: Chronic Obstructive Pulmonary Disease (COPD) is characterized by high morbidity, disability, and mortality rates worldwide. RNA-binding proteins (RBPs) might regulate genes involved in oxidative stress and inflammation in COPD patients. Single-cell transcriptome sequencing (scRNA-seq) offers an accurate tool for identifying intercellular heterogeneity and the diversity of immune cells. However, the role of RBPs in the regulation of various cells, especially AT2 cells, remains elusive.
MATERIALS AND METHODS: A scRNA-seq dataset (GSE173896) and a bulk RNA-seq dataset acquired from airway tissues (GSE124180) were employed for data mining. Next, RNA-seq analysis was performed in both COPD and control patients. Differentially expressed genes (DEGs) were identified using criteria of fold change (FC ≥ 1.5 or ≤ 1.5) and P value ≤ 0.05. Lastly, Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and alternative splicing identification analyses were carried out.
RESULTS: RBP genes exhibited specific expression patterns across different cell groups and participated in cell proliferation and mitochondrial dysfunction in AT2 cells. As an RBP, AZGP1 expression was upregulated in both the scRNA-seq and RNA-seq datasets. It might potentially be a candidate immune biomarker that regulates COPD progression by modulating AT2 cell proliferation and adhesion by regulating the expression of SAMD5, DNER, DPYSL3, GBP5, GBP3, and KCNJ2. Moreover, AZGP1 regulated alternative splicing events in COPD, particularly DDAH1 and SFRP1, holding significant implications in COPD.
CONCLUSION: RBP gene AZGP1 inhibits epithelial cell proliferation by regulating genes participating in alternative splicing in COPD.
Clear gel in water comprises the reaction product formed by rapid intensive agitation in water of a cationic polymer (C) having a positive charge and an anionic polymer (A) having a negative charge. (C) is poly(diallyldimethylammonium chloride (C1), poly(diallyldimethylammonium chloride-co-acrylamide (C2), or quat. ammonium cellulose ether polymer (C3). (A) is a polysulphonic acid or alginic acid. Gel on dilution with water has a viscosity greater than that attributable to the separate components.S Polymers, free of interfering ingredients such as salts and other ionic materials, are rapidly mixed in water, e.g. as aq. solns., at at least 500 rpm.
PURPOSE:A hypoglycemic agent containing a polysaccharide which is a water-soluble component of a plant belonging to Dioscorea genus, Dioscoreaeae family, as an active component. CONSTITUTION:The raw or dried rhizome or propagule of a plant belonging to Dioscorea genus, Dioscoreaeae family (e.g. Dioscorea japonica, Dioscorea batatas, Dioscorea bulbifera, Dioscorea gracillima) is crushed or pulverized, and extracted with water or aqueous organic solvent (e.g. methanol). The amount of the extractant is 1.5-4 times volume of the raw material. The extracted liquid is concentrated and dried under reduced pressure, and further purified to obtain the polysaccharide useful as the active component. A hypoglycemic agent having little side effect can be prepared by using said polysaccharide as the active component. Dose: 10-300mg, preferably 30-100mg of the active component daily in 2-3 divided doses, in the form of an oral drug such as tablet, capsule, syrup, etc., or an injection.
Crohn's disease is often treated with glucocorticoids or mesalazine. Both drugs are indicated for active Crohn's disease. Treatment with mesalazine is indicated for the treatment of mildly to moderately active Crohn's disease. Budesonide 9 mg/day or mesalazine 4.5 g/day are better than lower doses.

So far only one trial compares the efficacy and safety of budesonide and 5-ASA. The result of this trial is that budesonide is more effective in inducing remission than mesalazine. The primary objective of this trial is to confirm this result for other presentations of budesonide and mesalazine; i.e. Budenofalk® capsules (9 mg/day) and Salofalk® tablets (Eudragit-L-coated oral mesalazine; 4.5 g/day) in moderately active Crohn's disease. Mesalazine is used in this trial as a comparator.
Cerebral hemorrhage, subarachnoid hemorrhage, and stroke have occurred in patients treated with 5-HT1 agonists, and some have resulted in fatalities. In a number of cases, it appears possible that the cerebrovascular events were primary, the 5-HT1 agonist having been administered in the incorrect belief that the symptoms experienced were a consequence of migraine, when they were not. Also, patients with migraine may be at increased risk of certain cerebrovascular events (e.g., stroke, hemorrhage, transient ischemic attack). Discontinue rizatriptan benzoate if a cerebrovascular event occurs.   
As with other acute migraine therapies, before treating headaches in patients not previously diagnosed as migraineurs, and in migraineurs who present with atypical symptoms, care should be taken to exclude other potentially serious neurological conditions. Rizatriptan benzoate should not be administered to patients with a history of stroke or transient ischemic attack [see  Contraindications (4)].
Sixty-five American Indians with diabetes were enrolled. Each participant was randomly assigned to 1 of 3 study arms: (1) the in-person education group, (2) the online education group, and (3) a control group. The in-person intervention group attended four class sessions addressing numeracy skills used in the management of diabetes (e.g., counting carbohydrates). The online education group completed a single online module providing training on diabetes-related numeracy skills. The control group received written diabetes educational materials. The investigators collected data at baseline, then again immediately after intervention participation (in-person or online classes), and one final time about three months after the conclusion of the intervention. The investigators will conduct analyses to determine if intervention participants experienced positive changes in diabetes numeracy (the primary outcome) as well as several secondary outcome measures following intervention. Secondary outcomes include: diabetes knowledge, self-efficacy, outcome expectancies, readiness to change, self-care behavior, and clinical outcomes (i.e., body mass index, blood pressure, blood sugar \[A1c\]) . The investigators also will assess whether change in numeracy predicts change in these secondary outcomes.
Subjects will receive 1.5 mg tivozanib once daily beginning on Day 1 for 3 weeks followed by 1 week off treatment. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks.
Distribution: In four healthy male volunteers, receiving an intravenous administration of 30 seconds in duration, the arterial blood level profile for Fludeoxyglucose F 18 decayed triexponentially. The effective half-life ranges of the three phases were 0.2-0.3 minutes, 10-13 minutes with a mean and standard deviation (STD) of 12 (±) 1 min, and 80-95 minutes with a mean and STD of 88 (±) 4 min. 

Plasma protein binding of Fludeoxyglucose F18 has not been studied. 

Metabolism: Fludeoxyglucose F 18 is transported into cells and phosphorylated to [18F]‑FDG-6- phosphate at a rate proportional to the rate of glucose utilization within that tissue. [F18]-FDG-6-phosphate presumably is metabolized to 2-deoxy-2-[F18]fluoro-6‑phospho-D-mannose ([F18]FDM-6-phosphate). 

Fludeoxyglucose F18 Injection may contain several impurities (e.g., 2-deoxy-2-chloro‑D-glucose (ClDG)). Biodistribution and metabolism of ClDG are presumed to be similar to Fludeoxyglucose F 18 and would be expected to result in intracellular formation of 2‑deoxy-2-chloro-6-phospho-D-glucose (ClDG-6-phosphate) and 2-deoxy-2-chloro-6‑phospho-D-mannose (ClDM-6-phosphate). The phosphorylated deoxyglucose compounds are dephosphorylated and the resulting compounds (FDG, FDM, ClDG, and ClDM) presumably leave cells by passive diffusion. Fludeoxyglucose F18 and related compounds are cleared from non-cardiac tissues within 3 to 24 hours after administration. Clearance from the cardiac tissue may require more than 96 hours. Fludeoxyglucose F18 that is not involved in glucose metabolism in any tissue is then excreted in the urine. 

Elimination: Fludeoxyglucose F18 is cleared from most tissues within 24 hours and can be eliminated from the body unchanged in the urine. Within 33 minutes, a mean of 3.9% of the administrated radioactive dose was measured in the urine. The amount of radiation exposure of the urinary bladder at two hours post-administration suggests that 20.6% (mean) of the radioactive dose was present in the bladder. 

Special Populations: The pharmacokinetics of Fludeoxyglucose F18 Injection have not been studied in renally-impaired, hepatically impaired or pediatric patients. Fludeoxyglucose F18 is eliminated through the renal system. Avoid excessive radiation exposure to this organ system and adjacent tissues. 

The effects of fasting, varying blood sugar levels, conditions of glucose intolerance, and diabetes mellitus on Fludeoxyglucose F18 distribution in humans have not been ascertained [see Warnings and Precautions (5.2)].